文献速递乳腺癌

早期HER2阳性乳腺癌辅助曲妥珠单抗9周对比1年联合化疗:SOLD随机临床试验

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

SOLD试验纳入2174例HER2阳性早期乳腺癌患者,随机比较9周与1年曲妥珠单抗(联合相同化疗)的疗效与安全性。中位随访5.2年,9周组DFS非劣效性未获证实(HR 1.39;90% CI 1.12-1.72),但心脏安全性更优。

要点

  • 9周曲妥珠单抗对比1年未能证明DFS非劣效(HR 1.39;90% CI 1.12-1.72)。
  • 1年组心脏衰竭36例(3%),9周组21例(2%),9周组LVEF维持更好。
  • 多西他赛剂量与DFS存在交互:80 mg/m2时9周组DFS较差,100 mg/m2时两组相似。

核心结论

  • 在联合相同化疗时,9周曲妥珠单抗对比1年未能证明DFS非劣效。
  • 9周组心脏安全性优于1年组。
  • 多西他赛剂量与曲妥珠单抗疗程的交互作用需进一步研究。

研究设计与样本

  • 开放标签、1:1随机临床试验,纳入HER2阳性早期乳腺癌女性。
  • 两组化疗相同:3周期3周一次多西他赛(80或100 mg/m2)联合曲妥珠单抗9周,序贯3周期氟尿嘧啶+表柔比星+环磷酰胺;此后9周组不再用曲妥珠单抗,对照组继续至1年。
  • 计划样本量2168例(单侧检验,相对非劣效界值1.3),2008年1月3日至2014年12月16日从7国纳入2176例,分析2174例。
  • 主要终点为DFS,采用Cox模型和非劣效性方法比较;次要终点包括远处无病生存、总生存、心脏DFS和安全性。

主要发现

  • 中位年龄56岁(IQR 48-64),中位随访5.2年(IQR 3.8-6.7)。
  • 9周组DFS非劣效性未获证实:HR 1.39;双侧90% CI 1.12-1.72。
  • 远处无病生存和总生存两组间无实质差异。
  • 1年组和9周组分别有36例(3%)和21例(2%)患者发生心脏衰竭,9周组左心室射血分数维持更好。
  • 多西他赛剂量与DFS存在交互:9周组中80 mg/m2者DFS劣于1年组,100 mg/m2者与1年组相似。

关键数值与推荐

  • 非劣效性检验采用单侧检验,相对非劣效界值1.3,计划样本量2168例。
  • DFS非劣效性未成立:HR 1.39;双侧90% CI 1.12-1.72。
  • 心脏衰竭发生率:1年组3%(36例),9周组2%(21例)。

临床怎么用

  • 不推荐以9周曲妥珠单抗替代1年标准辅助疗程,因DFS非劣效性未获证实。
  • 对于心脏毒性风险较高的患者,9周方案心脏安全性更好,但需权衡DFS风险。
  • 多西他赛80 mg/m2联合9周曲妥珠单抗的DFS较差,该剂量组合应避免或进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Trastuzumab plus chemotherapy is the standard adjuvant treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. While the standard duration of trastuzumab treatment is 12 months, the benefits and harms of trastuzumab continued beyond the chemotherapy are unclear. OBJECTIVE: To evaluate the efficacy and safety of adjuvant trastuzumab continued beyond chemotherapy in women treated with up-front chemotherapy containing a taxane and trastuzumab. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized (1:1) clinical trial including women with HER2-positive breast cancer. Chemotherapy was identical in the 2 groups, consisting of 3 cycles of 3-weekly docetaxel (either 80 or 100 mg/m2) plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide. Thereafter, no trastuzumab was administered in the 9-week group, whereas controls received trastuzumab to complete 1 year of administration. Disease-free survival (DFS) was compared between the groups using a Cox model and the noninferiority approach. The estimated sample size was 2168 patients (1-sided testing, with a relative noninferiority margin of 1.3). From January 3, 2008, to December 16, 2014, 2176 patients were accrued from 7 countries. INTERVENTION: Docetaxel plus trastuzumab for 9 weeks, followed by 3 cycles of fluorouracil, epirubicin, and cyclophosphamide in both groups. Controls continued trastuzumab to 1 year. MAIN OUTCOMES AND MEASURES: The primary objective was DFS; secondary objectives included distant disease-free survival, overall survival, cardiac DFS, and safety. RESULTS: In the 2174 women analyzed, median age was 56 (interquartile range [IQR], 48-64) years. The median follow-up was 5.2 (IQR, 3.8-6.7) years. Noninferiority of the 9-week treatment could not be demonstrated for DFS (hazard ratio, 1.39; 2-sided 90% CI, 1.12-1.72). Distant disease-free survival and overall survival did not differ substantially between the groups. Thirty-six (3%) and 21 (2%) patients in the 1-year and the 9-week groups, respectively, had cardiac failure; the left ventricle ejection fraction was better maintained in the 9-week group. An interaction was detected between the docetaxel dose and DFS; patients in the 9-week group treated with 80 mg/m2 had inferior and those treated with 100 mg/m2 had similar DFS as patients in the 1-year group. CONCLUSIONS AND RELEVANCE: Nine weeks of trastuzumab was not noninferior to 1 year of trastuzumab when given with similar chemotherapy. Cardiac safety was better in the 9-week group. The docetaxel dosing with trastuzumab requires further study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00593697.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Joensuu H, Fraser J, Wildiers H, et al. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29852043. doi:10.1001/jamaoncol.2018.1380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。